摘要
目的探讨参麦注射液治疗2019新型冠状病毒(2019-nCoV)感染合并心肌炎可能的作用靶点和机制。方法采用网络药理学的研究方法,首先通过中药系统药理学数据库与分析平台和中药整合药理学平台筛选参麦注射液中的主要活性成分及其作用靶点,通过GeneCards数据库和OMIM数据库筛选2019冠状病毒病(COVID-19)和心肌炎两种疾病的主要靶点,使用R语言筛选参麦注射液作用于COVID-19感染心肌炎的相关靶点(即交集基因),采用Cytoscape3.6.0软件构建“药物-成分-靶点-疾病”网络图,将得到的靶点再利用String数据库进行蛋白互作网络分析,并利用R语言对交集基因进行基因本体功能分析和京都基因与基因组百科全书通路分析。结果经过筛选得到17个参麦注射液作用于2019-nCoV感染心肌炎的相关靶点,基因本体功能分析得到42个具有统计学意义(P<0.05)的生物学过程,以及京都基因与基因组百科全书通路得到154条信号通路。结论本研究探讨了参麦注射液治疗2019-nCoV感染心肌炎的有效成分,预测其主要是通过B淋巴细胞瘤-2基因、丝裂原活化蛋白激酶3、白介素-6潜在靶点,调控肿瘤坏死因子、白介素-17信号通路来调节免疫功能,揭示了多层次、多靶点和多途径的作用机制,为临床应用及进一步探究其作用机制奠定了基础。
Objective To explore the possible targets and mechanism of shenmai injection for COVID-19 and myocarditis.Methods By using network pharmacology,the main active components and target genes of shenmai injection were screened by TCMSP and TCMIP platform.The main target genes for COVID-19 and myocarditis were screened by GeneCards database and OMIM database.R software was used to predict the key targets of shenmai injection intervention on COVID-19 and myocarditis.Cytoscape3.6.0 software was used to construct a“drug-components-targets-diseases”network map.The obtained target genes were analyzed by the String database for protein interaction network analysis,and the R software was used to analyze the GO function and KEGG pathway of the intersection genes.Results 17 targets of shenmai injection in treatment of COVID-19 and myocarditis were screened.The GO analysis revealed 42 statistically significant(P<0.05)biological processes,KEGG analysis yielded 154 signal pathways.Conclusion This study explored the effective components of shenmai injection for COVID-19 and myocarditis,and predicted that it mainly regulates immune function through potential targets such as BCL2,MAPK3,IL-6,and other potential targets,and regulate signal pathways such as TNF and IL-17,revealing the multi-level,multi-target and multi-channel mechanism of shenmai injection.This study laid a foundation for clinical application and further exploration of its mechanism.
作者
张艺文
蔡琳
秦莉
杨晓倩
汪汉
ZHANG Yiwen;CAI Lin;QIN Li;YANG Xiaoqian;WANG Han(Department of Cardiology,The Third People's Hospital of Chengdu,The Affiliated Hospital of Southwest Jiaotong University,Southwest Jiaotong University Medical School,Chengdu 610031,Sichuan,China)
出处
《心血管病学进展》
CAS
2020年第10期1101-1105,共5页
Advances in Cardiovascular Diseases
基金
四川省科技厅面上项目(2019YJ0634)。